Cogent Biosciences, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Cogent is a clinical-stage biotechnology company developing precision therapies. It has no products approved for sale and reported no product revenue.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Research and development expense | $52.7 million | $36.0 million |
| General and administrative expense | $9.7 million | $7.2 million |
| Total operating expenses / operating loss | $62.4 million | $43.2 million |
| Interest income | $4.1 million | $2.3 million |
| Net loss | $58.3 million | $38.6 million |
| Net loss per share, basic and diluted | $0.62 | $0.55 |
| Cash used in operating activities | $52.5 million | $39.5 million |
At March 31, 2024, cash and cash equivalents were $215.8 million and marketable securities were $219.9 million, totaling $435.7 million. Total assets were $476.1 million; total liabilities were $53.8 million, primarily operating lease liabilities and current payables/accruals. No debt was reported. With no product sales, revenue margins are not applicable; the filing does not provide a meaningful operating margin.
Material changes versus the prior period
- Net loss increased by $19.8 million year over year. R&D expense rose $16.7 million, mainly from bezuclastinib manufacturing and development, clinical-trial enrollment and activity, and pipeline research. G&A increased $2.5 million, primarily due to personnel costs.
- Operating cash use increased by $13.0 million. Higher interest income partly offset operating expenses.
- Financing provided $214.1 million of cash, mainly from the February private placement. Net proceeds were approximately $213.4 million after offering costs.
- Common shares outstanding increased to 95.6 million from 86.1 million at year-end 2023. Series B preferred shares are convertible into 20.58 million common shares subject to stockholder approval to increase authorized common shares. Including preferred shares and outstanding pre-funded warrants, the company reported 135.4 million shares outstanding on an as-converted basis.
Outlook, programs and risks
- Management estimates existing cash, cash equivalents and marketable securities will fund operations into 2027 and through clinical readouts from the registration-directed SUMMIT, PEAK and APEX trials. The estimate depends on assumptions; the company expects significant ongoing losses and may need additional funding.
- SUMMIT Part 2, a registration-directed Non-AdvSM study of bezuclastinib, was enrolling; enrollment was expected to finish in Q2 2025, with top-line results expected by year-end 2025. APEX Part 2 in AdvSM was expected to complete enrollment by year-end 2024, with results expected by mid-2025. PEAK, a Phase 3 GIST study, was expected to complete enrollment by year-end 2024, with results expected by year-end 2025.
- Management reported encouraging Phase 2 SUMMIT Part 1b symptom, quality-of-life and biomarker results, and previously reported APEX and PEAK clinical activity. These are interim study findings, not regulatory approvals or proof of future outcomes.
- CGT4859, the FGFR2 clinical candidate, was undergoing IND-enabling work; the company expected to begin a clinical trial by year-end 2024. An ErbB2 candidate had been selected, with IND-enabling studies expected to begin in mid-2024. PI3Kα work remained in preclinical development.
- Key risks include clinical safety, efficacy and enrollment; regulatory review and approval; manufacturing and supply; competition and intellectual-property protection; and the need for future capital. Additional equity financing could dilute shareholders, while collaborations could require relinquishing product or technology rights. Management reported no material changes to the risk factors in its 2023 Form 10-K.
- No material legal proceedings were reported. The contingent value rights expired in August 2023 with no further payments expected. The company reported no off-balance-sheet arrangements and stated that disclosure controls were effective.
Important facts for investors to verify
- Whether trial enrollment, timelines and readouts for SUMMIT, APEX and PEAK remain on schedule, and how the clinical data mature.
- Whether the reported cash runway into 2027 remains achievable as trial and development spending increases.
- The impact of the Series B conversion conditions and potential dilution from preferred shares, options, restricted stock units and pre-funded warrants.
- Future financing needs, financing terms and any resulting dilution or restrictions on company rights.
- Regulatory feedback on the SUMMIT patient-reported outcome measure and the progress of the FGFR2 and ErbB2 programs toward clinical testing.